Clinical Trial Update: Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib [Phase 2]

View source ↗

Summary

Phase 2 study evaluating osimertinib plus savolitinib for EGFR-mutant, MET-positive non-small cell lung cancer after prior osimertinib, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Savolitinib (savolitinib)
• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-10